Both BMSN and REGEN have a lot of debt, no real source of income, and Koos does not have the greatest of track records when in comes to heading companies. I will say that Regen is in a much better position than they were one year ago. I actually owned both, even partaking in the spin-off. However, I sold all my shares in order to invest in Benitec since they are in clinical trial, and have SIGNIFICANT preclinical work to support their trial. Regen still needs the full IND, which I don't know if they have gotten yet, PLUS they still need to FUND their trial, which means a capital raise, and/or dilution may be on the way. If decelvax can make it into clinical trial, that may be when I jump back in. By then, we will have data back from Benitec on whether or not ddRNAi is effective...but all the preclinical and shrnai work by other pretty much is pointing to a big yes. If I were to jump in today, I would only be holding Regenersonally since they are actually much further ahead into getting a clinical trial underway. The two new doctors is a small start. What they need ais a green light for a clinical trial, and even then, they need to actually start one. Wish you all the best though!
News 
Market Data 
Discover 
